U.S. Markets close in 3 hrs 13 mins

Navidea Biopharmaceuticals, Inc (NAVB)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
0.3794-0.0056 (-1.4545%)
As of 12:42PM EDT. Market open.
People also watch
IMUCCLSNGALEMSTXCPRX
  • R
    RidgebackBoo
    RidgebackBoo
    Really NO reason to post on this stock until REAL news, not FAKE news.........but, IMO, looking at the one-year chart, I would "guestimate" that NAVB might go as low #$%$34. Just my "guestimate". I might just buy more if it goes below .38.....my average is .70/share right now.
  • J
    James
    James
    I think that if you don't like the products or the company as a whole you should just sell, I realize it is nerve racking but that's how it goes.
  • J
    James
    James
    Cardinal Health made NAVB ligament with it's products by their purchase. They are in better shape than many other biotechs sometimes I forget that .
  • B
    BioLover
    BioLover

    SNOA (MC $23 M) (Cash $13 M) Shares Out: 4.3 M / 17 FDA approved products some of them are in early launch phase plus additional Product launches expected within 6 months / Profitable in 2018 = 1000%+ UPSIDE POTENTIAL..GLTA

    Sonoma Pharma (Nasdaq: SNOA)

    Market Cap: 22.1 Million
    Cash: $12.6 Million
    Price: $5.15

    Shares Out : 4.3 Million

    Presentation
    http://ir.sonomapharma.com/common/download/download.cfm?companyid=ocls&fileid=945547&filekey=F57B6874-6CD1-4205-A160-8E08BBB7A928&filename=SonomaPharma_Investor_presentation_13June2017.pdf

    Fact Sheet
    http://files.shareholder.com/downloads/OCLS/4977255852x0x231236/39d834a3-8462-40ee-8650-e0945b6facd5/Sonoma_Fact_Sheet.pdf

    Driving to commercial EBITDAS breakeven, without dilution

    Grow current product portfolio with all sales people

    •Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment
    •Mondoxyne for severe acne –launched late 2015
    •Ceramax for skin repair in atopic dermatitis–launched in April 2016
    •SebuDerm for seborrhea dermatitis –launched in November 2016

    Launch 3 New Products –our product pipeline –one every other quarter

    •Launching Loyon–Fall 2017
    •Ceramax in foam and gel forms –Q4 2017 & Q1 2018

    Launch and Grow New and Current Products: During fiscal year 2017, we launched four new dermatology products, including SebuDerm™, Ceramax™, Lasercyn™ Gel and Lasercyn™ Dermal Spray, bringing us to a total of eight dermatology products for the treatment of atopic and seborrheic dermatitis, scar management, surgical procedures, severe acne and “state of the art” skin repair technology. We also obtained three new FDA clearances, now totaling 16 overall. Our strong intellectual property portfolio consists of 63 issued patents and 33 patent applications pending.

    We plan to launch our new FDA approved product Loyon® (a skin descaler currently marketed in Europe) in the upcoming months and have a strong product pipeline of several product line improvements, including a line extension of Ceramax™. All in all, we believe this could possibly be our best product line of new FDA approved dermatology and skincare products yet, and we believe our innovation plan will help lead us to profitability.

  • T
    TurboTime
    TurboTime
    Imageotter-ful
  • D
    Duke of Westchester
    Duke of Westchester
    another trading day, another down day for NeoPoop. Same old story... just like Thomas.
  • R
    RN
    RN
    bob
    so far it's as you say , going down
    when does the reverse start and we go back up
  • D
    Duke of Westchester
    Duke of Westchester
    Moving all my funds to GE. This stock has done nothing but lose all my money, cause worry, wife left and children wont see me. Thank you NAVB, for nothing.
  • D
    Duke of Westchester
    Duke of Westchester
    Market up 200 points, Navb down again. Last one out, turn out the lights.
    This stock has been worse than a cheating girlfriend....
  • D
    Duke of Westchester
    Duke of Westchester
    Stocks are up 150 points! Why is NAVBpoop down? WHY WHY WHY!?
  • J
    James
    James
    Partner that has some clout means a great deal they keep talking about it, I hope that comes true the sooner the better but it has to be someone with money .I've been here for a very long time.
  • A
    Anonymous
    Anonymous
    30 Cents ?????? Folks are beginning to realize that this ""company"" is going to be out of cash by the end of 2017.
  • B
    Bob
    Bob
    This stock has gone stagnant with a price range from 40-43 cents and so has this message board. Everybody that has ever been involved with NAVB knows another run up in price is coming. It happens all the time. I just hope there is not a tax loss sell off to drive the price down to low/mid 30's. This stock has been manipulated up and down for years and now they finally have a product with another product maybe next year. Europe is rolling out along with Asiaso I can pretty much guarantee another run in the price. The question is when?To hold off the tax loss selling, the early November quarterly report will need some revenues. We know the 1.67 million from cardinal will be there and some grants but we need at least something in Europe to get the ball rolling. Partnerships seem to take many months and sometimes longer to get the lawyers to agree on anything. Those money hungry lawyers love to spread out the time to book more payments. They are the #$%$ of the earth. They are almost as bad as politicians but sometimes a lawyer can make you some money.
  • J
    James
    James
    anybody who puts money in a biotech who can't afford to loose it is crazy........5% chance of success.
  • d
    donmiller90
    donmiller90
    what does this company have to do to increase PPS other than tricks with reverse split and what is the plan to get it done by when?
  • C
    Christopher
    Christopher
    I'm beginning to think that no one grasps the importance of the IV use approval. It's truly what will drive everything. Once approved, payloads will be attached. Once approved for one disease, it will be used for others. This is why it's been referenced as the 'backbone'. It's a beurocractic FDA that they must gain favor with. Timing is everything.
  • C
    Christopher
    Christopher
    Has anyone heard if BIND bankruptcy got finalized today in courts?
  • T
    TurboTime
    TurboTime
    I may have missed a couple of items, please feel free to add in this thread.
    Thanks.
    Question 1, regarding Sinotau lawsuit. Answer, NAVB in active discussions to resolve lawsuit with Sinotau as quickly as possible.
    Question 2, Euro Sales figures, will announce sales numbers on a quarterly basis, as of today nothing to report from Euro. Ramp is moving up and distributions has started. Numbers should start to come in as early as next quarter.
    Question KS Therapeutic timing, Answer, received 2 grants related to KS, one imaging 2nd therapeutic. File IND for KS Therapy in the next 12 months, based on the clinical package discussed with FDA.
    Question, Partnerships; Answer, depending on the product and opportunity , one company has come to NAVB on the imaging side, another company which has a therapeutic product is interested in both imaging and therapeutic partnership. NAVB to continue to develop product which much is funded by other agencies by the work of Fred and his team. Have very good data now to go out and seek additional grants and partnerships.
    Question, value drivers of a JV/partnership and timing; Answer, yes, our biz model is to sign those partnerships to help in resources, money, etc. We are not in a position that we HAVE to partner, want to partner with the right organization with the right terms this go around. We are in discussions and negotiations with multiple partnerships.
    Question; status update of MT spin-off; Answer, help raise funds to aggressively develop products, generate value for MT which in-turn for NAVB stock and shareholders, still have a large short position which should significantly be reduced when the spin off is executed.
    Question, Is lawsuits hindering partnerships, Answer; it doesn't come up in discussions now that the CRG is finalized and liens are released. Sinotau legal should be resolved. NAVB was increased its IP significantly which is the main topic of discussion with potential partnerships.

    For Future Quarterly Calls, questions can be submitted via web to be address at the end of the ppt..
  • D
    Duke of Westchester
    Duke of Westchester
    Doubting Thomas a Judas in disguise! Shame on your lies young Tommy.now go to your room. Holders of other stocks feel bad their stocks down. We feel bad with Navb, every day as it continues to disappoint.
  • T
    TurboTime
    TurboTime
    Navidea ended the 2nd quarter with $7.6 million in cash and investments, not including the quarterly guaranteed earnout payment of $1.67 million from Cardinal Health 414 which was received after the quarter ended. $9.27M in Cash..